NEW YORK, April 15, 2014 /PRNewswire/ -- Nuvilex, Inc.
(OTCQB: NVLX), a clinical-stage biopharmaceutical competitor
is focused on developing and preparing to commercialize treatments
for cancer and diabetes based upon a proprietary cellulose-based
live-cell encapsulation technology, called Cell-in-a-Box®. This
unique technology is intended for use as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Researchers have recently estimated that the value of the
pancreatic cancer market in the US and 5EU (France, Germany, Italy, Spain,
and the UK) in 2012 was $529m. This
market is defined as sales of branded drugs and major generic
regimens commonly prescribed for pancreatic cancer patients across
the six major markets (6MM). Just over half of these sales,
$275m (52%), were generated in the
US, while sales in the 5EU were estimated at $254m (48%).
The Company is now at a point where investors are seeking
tangible results to justify robust speculation about the near term
and ultimate end game outcome for NVLX.
An analyst report which details key attributes of the
technology, an overview of the company and analyst recommendation
can be viewed in its entirety by using the link below. There is no
cost required to view this report.
http://bit.ly/NVLX-AnalystReport
Copy and paste to browser may be required.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward- looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is written and authored by
Michael Andereg, CFA. An outsourced research services provider
represented by Michael Andereg, CFA, provided Small Cap Street, LLC
this article or report. However, we are only human and are prone to
make mistakes. If you notice any errors or omissions, please notify
us below. Small Cap Street, LLC and BrokerBank Securities, Inc. are
not entitled to veto, interfere or alter the articles, documents or
report once created and reviewed by the outsourced research
provider represented by Michael Andereg, CFA.
If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at admin@smallcapir.com. For any urgent concerns or inquiries,
please contact us at admin@smallcapir.com.
NO WARRANTY OR LIABILITY ASSUMED
NVLX has not compensated Small Cap Street, LLC, BrokerBank
Securities, Inc., or Michael Andereg, CFA for the creation or
dissemination of this report. Small Cap Street, LLC and BrokerBank
Securities, Inc., is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. Small Cap Street, LLC and BrokerBank
Securities, Inc. do not hold any positions in NVLX. No liability is
accepted by Small Cap Street, LLC and BrokerBank Securities, Inc.
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Small Cap Street, LLC and BrokerBank
Securities, Inc. expressly disclaims any fiduciary responsibility
or liability for any consequences, financial or otherwise arising
from any reliance placed on the information in this document. Small
Cap Street, LLC and BrokerBank Securities, Inc. do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
Small Cap Street, LLC is the party responsible for hosting the
full analyst report. BrokerBank Securities in the party responsible
for issuing the press release and Michael Andereg, CFA, is the
author of research report. Small Cap Street, LLC has compensated
Michael Andereg, CFA two hundred
dollars and fifty dollars for
the right to disseminate this report. BrokerBank Securities has
been compensated one hundred dollars
to issue press release by Small Cap Street, LLC. Information in
this release is fact checked and produced on a best efforts basis
by Michael Andereg, CFA.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
BrokerBank Securities, Inc. is a member of the Financial
Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.